Clinical trials
Amyotrophic Lateral Sclerosis clinical trials
Below are recruiting amyotrophic lateral sclerosis clinical trials, each written for real people, not researchers. We’re tracking 189 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03233646Recruiting
Retina scans in memory and nerve disorders
This study uses pictures of the back of your eye (retinal imaging) to look for differences in people with neurodegenerative diseases and compares them with people without these conditions. It may help researchers understand eye changes that could connect to brain or nerve health.
Durham, North CarolinaAges 18 years+ - NCT05395624RecruitingPhase 1/Phase 2
Safety imaging study of a PET tracer in ALS, Alzheimer, MS, Parkinson
This early-phase study tests the safety of a radioactive tracer (“18F-OP-801”) and how the tracer moves through the body (biodistribution) in people with ALS, Alzheimer’s disease, multiple sclerosis, Parkinson’s disease, and in healthy volunteers. It also measures how the body processes the tracer (“pharmacokinetics”) to support future studies.
San Francisco, CaliforniaAges 18–80 - NCT07202494Recruiting
Brain aging and resilience MRI study
This study uses powerful MRI scans to understand how the brain ages and why some people stay healthy while others develop neurological diseases like multiple sclerosis or Alzheimer's. It compares healthy volunteers to people with certain conditions, and all participants get a detailed brain MRI.
MarseilleAges 18–90 - NCT03366506Recruiting
Study factors linked to ALS development
This study looks at people who might have amyotrophic lateral sclerosis (ALS) to understand what factors are associated with how the condition starts and develops. If you have a suspected or confirmed ALS diagnosis, it may help researchers learn what influences ALS and potentially guide future prevention or care.
JerusalemAges 12–120 - NCT07161999RecruitingPhase 2/Phase 3
COYA 302 treatment for ALS
This study tests an experimental treatment called COYA 302 for ALS. It aims to see if it can slow down the worsening of muscle weakness and improve daily function. It might be an option for people in the earlier stages of ALS.
Phoenix, ArizonaAges 18–80 - NCT03865420Recruiting
Genetic risk study for families affected by ALS
This study looks at genetic risk for amyotrophic lateral sclerosis (ALS) in families. It may help researchers understand who carries ALS-related gene changes and how that affects future care.
New York, New YorkAges 18–105 - NCT06765564Recruiting
Study of stem cell therapy for amyotrophic lateral sclerosis (ALS) progression
This study tests whether a new treatment using special motor neuron cells made from stem cells (iPSCs) can help people with ALS. The cells will be transplanted into the spinal cord to try to slow the disease and improve function.
Shanghai, Shanghai MunicipalityAges 18–60 - NCT07674667RecruitingPhase 1/Phase 2
Testing a treatment to restore UNC13A function in ALS
This trial tests a new treatment aimed at restoring the function of a gene called UNC13A in people with ALS. It involves multiple clinic visits, MRI scans, and spinal taps to see if the treatment is safe and may slow the disease.
MunichAges 18–75 - NCT06609213Recruiting
Testing a nutrition drink before feeding tube placement in ALS
This trial tests if drinking a special nutrition formula for a few weeks before getting a feeding tube can help people with ALS tolerate tube feeding better. It aims to reduce side effects like bloating or discomfort.
Fort Lauderdale, FloridaAges 18 years+ - NCT07743268Enrolling by invitationPhase 1/Phase 2
Personalized gene therapy for ALS linked to TARDBP
This trial tests a personalized medicine approach for people with ALS caused by changes in the TARDBP gene. The treatment uses a custom-made molecule to target the genetic cause and may help slow the disease.
St Louis, MissouriAges Any age - NCT06735014Recruiting
ALS imaging study to track disease progression
This study uses MRI brain scans to understand how ALS affects the brain over time. It may help researchers develop better ways to measure the disease.
Gainesville, FloridaAges 18 years+ - NCT06284161Recruiting
QCT scan for ALS diagnosis and monitoring
This study uses quantitative computed tomography (QCT), a special type of CT scan, to help diagnose ALS, understand how it affects the body, and track its progression over time. It is for people who may have ALS and meet specific diagnostic criteria.
Clermont-FerrandAges 18 years+ - NCT06578195Recruiting
Assess all ALS study
This study follows people with ALS and healthy volunteers over time to understand the disease better. You can join from home using a smartphone or computer.
Birmingham, AlabamaAges 18 years+ - NCT07322003RecruitingPhase 3
Pridopidine for ALS: Phase 3 trial testing safety and effectiveness
This trial is testing if an oral medication called pridopidine can slow the progression of ALS. It is for people recently diagnosed with ALS who have mild to moderate breathing function and meet specific risk scores.
Phoenix, ArizonaAges 18–80 - NCT07142291RecruitingPhase 2
Cromolyn inhaler for early ALS
This trial tests if an inhaled drug called cromolyn can help people with early-stage ALS. It is for people who can still breathe well and are not yet using a ventilator.
Scottsdale, ArizonaAges 18–75 - NCT03127267RecruitingPhase 3
Test of masitinib versus placebo for ALS
This Phase 3 study tests whether masitinib works better than an inactive pill (placebo) to slow ALS progression and keep it safe. It is meant for people recently diagnosed with ALS who meet specific breathing and function score requirements.
Birmingham, AlabamaAges 18–81 - NCT03174938Recruiting
BioFINDER 2 study for healthy aging and memory problems
This study uses brain scans and a spinal fluid test to better understand memory and thinking changes in different groups, from people with healthy thinking to early or established dementia. If you qualify, it may help researchers learn what’s driving these conditions and how they progress.
ÄngelholmAges 20–100 - NCT03567213Recruiting
CortiCom brain signal system for communication in severe paralysis
This trial tests a system that records brain signals to help people with severe paralysis and little or no speech communicate. It involves a surgical implant and frequent study visits to see if the system can work safely and reliably for communication.
Baltimore, MarylandAges 22–70 - NCT07703462Enrolling by invitationPhase 1/Phase 2
Personalized therapy for TARDBP ALS
This trial offers a custom-made treatment for people with ALS caused by a TARDBP gene mutation. It uses a personalized medicine approach to target the specific genetic cause of the disease.
Philadelphia, PennsylvaniaAges Any age - NCT04220190RecruitingPhase 2/Phase 3
Study drug made from your immune cells for ALS
This trial tests RAPA-501, a treatment made using your own immune cells, to slow progression of ALS. It may help by changing how your immune system responds in ALS.
Boston, MassachusettsAges 18 years+ - NCT04244630RecruitingPhase 2
Study to boost energy-making capacity in ALS
This Phase 2 trial tests a treatment meant to improve “energy production” in people with ALS. It aims to see whether increasing mitochondrial (cell energy) capacity can help ALS symptoms or progression.
Dallas, TexasAges 21–80 - NCT04302870RecruitingPhase 2/Phase 3
Test medicines for motor neurone disease using adaptive trial design
This study tests treatments for motor neurone disease (MND) and assigns people to different treatment arms in an adaptive way. It may help doctors find out which medicine works best and for whom.
Portadown, County ArmaghAges 18 years+ - NCT04715399Recruiting
Research study collecting data for neurodegenerative diseases
This study collects health information from people with neurodegenerative diseases, some family members, and healthy controls to help researchers better understand these conditions. It may help future diagnosis and research, and participation may include noninvasive checks and other procedures depending on your situation.
Philadelphia, PennsylvaniaAges 18 years+ - NCT04816227Recruiting
Study of immune cells in ALS and related movement problems
This study looks at immune cells (called macrophages) from people with ALS and certain related movement or nerve conditions. It aims to better understand how the disease works and may help researchers design future treatments.
ParisAges 18 years+
Hear when a new Amyotrophic Lateral Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for amyotrophic lateral sclerosis?
- Yes. Clin2 currently lists 189 recruiting amyotrophic lateral sclerosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a amyotrophic lateral sclerosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a amyotrophic lateral sclerosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.